Lung Cancer Screening and Prevention Act of 2025
Sponsors
Legislative Progress
In CommitteeMr. Buchanan (for himself, Mr. Kennedy of New York, Mr. …
Summary
What This Bill Does
The Lung Cancer Screening and Prevention Act of 2025 expands Medicare coverage to include additional lung cancer screening tests beyond what is currently covered. It gives the Secretary of Health and Human Services authority to approve coverage for any new FDA-cleared or FDA-approved lung cancer screening tests as preventive services.
Who Benefits and How
Medicare beneficiaries at high risk for lung cancer benefit by gaining access to a broader range of lung cancer screening options covered by Medicare. This could include newer, potentially more accurate diagnostic technologies as they become available.
Medical device and diagnostic companies that develop lung cancer screening tests benefit from an expanded market, as their FDA-approved products can now qualify for Medicare coverage through a streamlined process.
Healthcare providers offering lung cancer screening services may see increased patient volume as more screening options become available under Medicare.
Who Bears the Burden and How
Medicare/taxpayers will bear the costs of covering additional screening tests, though the bill allows the Secretary to set "frequency and payment limits" to control costs.
The Department of Health and Human Services takes on the administrative burden of evaluating and approving coverage for new screening tests, though the bill streamlines this by waiving certain evidence requirements.
Key Provisions
- Authorizes the HHS Secretary to cover any FDA-cleared or approved lung cancer screening test under Medicare Part B
- Allows the Secretary to determine which patients are "appropriate individuals" for each screening test
- Gives the Secretary authority to set payment limits and frequency restrictions
- Uses the existing national coverage determination process but waives certain evidence requirements (specifically the section 1861(ddd)(3)(B) determination)
- Allows the Secretary to consult with preventive services experts, including those from the Agency for Healthcare Research and Quality
Evidence Chain:
This summary is derived from the structured analysis below. See "Detailed Analysis" for per-title beneficiaries/burden bearers with clause-level evidence links.
Primary Purpose
This bill aims to expand lung cancer screening services under Medicare by allowing the Secretary to cover additional FDA-cleared or approved screening tests.
Policy Domains
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology